Table 1.
Patient characteristics and volumetric results for the whole MS patient cohort.
| All MS patients | RRMS patients | SPMS patients | p-value | |
|---|---|---|---|---|
| Sample size | 185 | 128 | 57 | |
| Females | 133 (71.9%) | 94 (73.4%) | 39 (68.4%) | |
| Age (years) | 43.5 (33.1; 50.3) | 39.8 (30.3; 46.0) | 51.6 (45.8; 61.1) | < 0.0001 |
| Disease duration (years) | 7 (2.4; 14) | 5 (2; 9) | 16 (11; 22.8) | < 0.0001 |
| EDSS | 2 (1; 4.5) | 1.5 (1; 2) | 6 (5; 7) | < 0.0001 |
| SDMT | −1 (−2; 0) | −0.5 (−1; 0) | −1.75 (−2.5; −1) | < 0.0001 |
| Treatment | ||||
| Yes | 108 (58.4%) | 84 (65.6%) | 24 (42.1%) | |
| No | 77 (41.6%) | 44 (34.4%) | 33 (57.9%) | |
| BP volume z-score | −1.13 (−2.50; −0.16) | −0.81 (−1.92; 0.12) | −2.14 (−3.43; −0.94) | < 0.0001 |
| GM volume z-score | −0.76 (−1.57; 0.13) | −0.60 (−1.28; 0.37) | −0.93 (−1.86; −0.15) | 0.0058 |
| WM volume z-score | −1.02 (−2.06; −0.09) | −0.81 (−1.58; 0.00) | −1.82 (−2.94; 0.71) | < 0.0001 |
| Corpus callosum volume z-score | −1.50 (−2.87; −0.52) | −1.21 (−2.31; 0.28) | −2.52 (−3.94; −1.34) | < 0.0001 |
| Caudate nucleus volume z-score | −0.89 (−1.87; 0.10) | −0.64 (−1.49; 0.12) | −1.57 (−2.39; 0.76) | < 0.0001 |
| Thalamus volume z-score | −2.46 (−3.99; −0.96) | −1.97 (−3.24; −0.63) | −3.50 (−5.14; −2.48) | < 0.0001 |
| Putamen volume z-score | −1.20 (−2.45; −0.25) | −0.91 (−1.76; −0.12) | −2.11 (−3.10; 0.79) | < 0.0001 |
Z-scores were calculated in comparison to the respective scanner-specific control cohort. All values are given as median and interquartile range or frequency and percentage. Symbol Digit Modalities Test (SDMT) was assessed for 183 of the 185 patients. Values are also given for the groups of relapsing-remitting MS (RRMS) and secondary-progressive MS (SPMS) patients separately. P-values indicate the difference between RRMS and SPMS patients, calculated with the Wilcoxon rank sum test. EDSS, Extended disability status scale; BP, brain parenchyma; GM, gray matter; WM, white matter.